{"url_path":"/sec/krys/8-k/2026-05-20/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1711279/0001711279-26-000047-index.html","accession_number":"0001711279-26-000047","cik":"0001711279","ticker":"KRYS","issuer_name":"Krystal Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1711279/0001711279-26-000047-index.html","primary_entity_key":"0001711279","primary_entity_name":"Krystal Biotech, Inc."},"word_count":355,"has_tables":true,"body_markdown":"Item 5.07    Submission of Matters to a Vote of Security Holders\n\nOn May 15, 2026, Krystal Biotech, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below are the matters acted upon at the Annual Meeting and the final voting results on each matter.\n\nProposal One: Election of Class III Directors\n\nThe Company’s stockholders elected Krish S. Krishnan and Christopher Mason as members of the Company’s Board of Directors as Class III directors for a three-year term. The results of the vote were as follows:\n\nNominee\n\nVotes For\n\nVotes Withheld\n\nBroker Non-Votes\n\nKrish S. Krishnan\n23,802,9203,079,1941,581,473\n\nChristopher Mason\n22,581,8544,300,2601,581,473\n\nProposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were as follows:\n\nVotes For\n\nVotes Against\n\nAbstentions\n\n28,443,15515,4344,998\n\nProposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation\n\nThe Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025, as disclosed in the Company’s proxy statement for the Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission. The results of the vote were as follows:\n\nVotes For\n\nVotes Against\n\nAbstentions\n\nBroker Non-Votes\n\n25,679,3181,195,7887,0081,581,473\n\nProposal Four: Non-Employee Director Compensation Policy\n\nThe Company’s unaffiliated stockholders (i.e., excluding the members of the the Company’s board of directors and the defendants in the litigation entitled Corbin v. Janney, et al., C.A. No. 2025-1051-KSJM (Del. Ch.) who refrained from voting on this matter in their capacities as stockholders) approved the Company’s Non-Employee Director Compensation Policy. The results of the vote were as follows:\n\nVotes For\n\nVotes Against\n\nAbstentions\n\nBroker Non-Votes\n\n21,374,0212,349,5503,158,5431,581,473\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: May 19, 2026  KRYSTAL BIOTECH, INC.\n\n  By: /s/ Krish S. Krishnan\n\n  Name: Krish S. Krishnan\n\n  Title: Chairman and Chief Executive Officer"}